BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10156501)

  • 1. Price regulation in the pharmaceutical industry: prescription or placebo?
    Abbott TA
    J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
    Shajarizadeh A; Hollis A
    Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
    Coronado J; Jiménez-Martín S; Marín PL
    Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should the US allow prescription drug reimports from Canada?
    Pecorino P
    J Health Econ; 2002 Jul; 21(4):699-708. PubMed ID: 12146598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry.
    Thomas LG
    Pharmacoeconomics; 1994; 6 Suppl 1():67-70. PubMed ID: 10155588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995-2007.
    Puig-Junoy J; López-Valcárcel BG
    Health Policy; 2014 Jun; 116(2-3):170-81. PubMed ID: 24641938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
    Boonen LH; van der Geest SA; Schut FT; Varkevisser M
    Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Problems in the regulatory policy of the drug market.
    Miziara NM; Coutinho DR
    Rev Saude Publica; 2015; 49():35. PubMed ID: 26083945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coordinating on lower prices: pharmaceutical pricing under political pressure.
    Ellison SF; Wolfram C
    Rand J Econ; 2006; 37(2):324-40. PubMed ID: 17290546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
    Gross DJ; Ratner J; Perez J; Glavin SL
    Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinion: price controls on prescription drugs.
    Franks B
    N J Med; 2004 Apr; 101(4):56, 55. PubMed ID: 15103791
    [No Abstract]   [Full Text] [Related]  

  • 19. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical prices continue to drive up supply costs.
    Hard R
    Hospitals; 1992 Mar; 66(5):49-50. PubMed ID: 1740289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.